PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of:

Attorney Docket No.: 3193.01US03

Unger

Confirmation No.: 2748

Application No.:

10/652,814

Examiner: Unknown

Filed:

August 29, 2003

Group Art Unit: 1636

For:

NANOCAPSULE ENCAPSULATION SYSTEM AND METHOD

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. § 1.56, and in addition to information disclosed in Applicant's Information Disclosure Statement filed March 12, 20004, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached Form PTO-1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This information is being filed before the mailing date of a first Office Action on the merits. No certification or fee is required.

Respectfully submitted,

Curtis B. Herbert, Ph.D., Esq.

Registration No. 45,443

Customer No. 24113
Patterson, Thuente, Skaar & Christensen, P.A. 4800 IDS Center
80 South 8th Street
Minneapolis, Minnesota 55402-2100
Telephone: (612) 349-3008

Please grant any extension of time necessary for entry; charge any fee due to Deposit Account No. 16-0631.

CERTIFICATE OF MAILING

02	
I hereby certify that this document is being deposited with mail in an envelope addressed to: Commissioner for Pater March 26, 2004	the United States Postal Service with sufficient postage as first class ats, P.O. Box 1450, Alexandria, VA 22313-1450 on
March 26, 2004	
Date of Deposit	Curtis B. Herbert, Ph.D., Esq.

Cubatitute for form 1440/DTO			<u>``</u>	Complete if Known				
Substitute for form 1449/PTO				U	Application Number	10/652,814		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT					Filing Date	August 29, 2003 Unger		
					First Named Inventor			
(Use as many sheets as necessary)					Art Unit	1636		
					Examiner Name	Unknown		
Sheeter	124 1		f	<u> </u>	Attorney Docket Number	3193.01US03		
MARKET	<u></u>		NON P	ATENT LITE	ERATURE DOCUME	ENTS	_	
EXAMINER INITIAL*	Cite No. ¹	Include item (bo	name of the a	uthor (in CAPITA, journal, serial, sy	L LETTERS), title of the art	icle (when appropriate), title of the e, page(s), volume-issue number(s),	T ²	
		AL-MO	USA, E	Γ. AL, (199	99) J Pharm Pharm	nacol 51(supplement):178,		
		"Eviden	ce for the	role of caveo	lae in gene delivery."			
	LEWIN ET. AL, (2000) Nature 18:410-414, "Tat peptide-derivatized magne nanoparticles allow in vivo tracking and recovery of progenitor cells."							
	·	nanopar	ticles allo	w in vivo trac	king and recovery of j	progenitor cells."		
		Caveola	MATVEEV ET. AL, (2001) Adv Drug Deliv Rev 49:237-250,"The role of caveolae and caveolin in vesicle-dependent and vesicle-independent trafficking."					
		WOLFF ET. AL, (1992) J Cell Sci 103:1249-59, "Expression of naked plasmids						
		by cultured myotubes and entry of plasmids into T tubules and caveolae of						
		mammalian skeletal muscle."						
-								
		1						
			· ·					
EXAMINER SIGNATURE					DATE CONSIDERED			
*CV A MINED	Initial if	roforonce co	ncidered wh	ether or not citatic		PEP 609. Draw line through citation if no	ot in	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not ir conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.